Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of CP-690,550 monotherapy in active rheumatoid arthritis
2008-007788-17Phase 3Completed
- Sponsor
- Pfizer
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tofacitinib in rheumatoid arthritis (RA) (3 arms), sponsored by Pfizer. Primary endpoint: ACR20 response rate at Month 3. Started Mar 2009; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2008-007788-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007788-17.